Why the study?
Does SPINT2 inhibit cleavage-activation and viral growth of influenza and HMPV in cell culture?
Does SPINT2 inhibit cleavage-activation and viral growth of influenza and HMPV in cell culture?
SPINT2 demonstrates potential as a broad-spectrum antiviral by inhibiting host proteases required for the activation of influenza and metapneumoviruses.
Answers are grounded in this paper and cite their sources.
SPINT2 inhibits influenza/HMPV fusion in vitro; leaves open in vivo efficacy and clinical translation.
Viruses possessing class I fusion proteins require proteolytic activation by host cell proteases to mediate fusion with the host cell membrane. The mammalian SPINT2 gene encodes a protease inhibitor that targets trypsin-like serine proteases. Here we show the protease inhibitor, SPINT2, restricts cleavage-activation efficiently for a range of influenza viruses and for human metapneumovirus (HMPV). SPINT2 treatment resulted in the cleavage and fusion inhibition of full-length influenza A/CA/04/09 (H1N1) HA, A/Aichi/68 (H3N2) HA, A/Shanghai/2/2013 (H7N9) HA and HMPV F when activated by trypsin, recombinant matriptase or KLK5. We also demonstrate that SPINT2 was able to reduce viral growth of influenza A/CA/04/09 H1N1 and A/X31 H3N2 in cell culture by inhibiting matriptase or TMPRSS2. Moreover, inhibition efficacy did not differ whether SPINT2 was added at the time of infection or 24 hours post-infection. Our data suggest that the SPINT2 inhibitor has a strong potential to serve as a novel broad-spectrum antiviral.
No takes yet. Share an insight, caveat, or question.
A 2019 study studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: